Regeneron Pharmaceuticals (REGN) financial statements
- FY2025 revenue
- $14.3B▲ +1.0%
- FY2025 net income
- $4.5B▲ +2.1%
- FY2025 diluted EPS
- $41.48▲ +8.2%
- FY2025 free cash flow
- $4.1B▲ +11.3%
Regeneron Pharmaceuticals income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 14,343 | 14,202 | 13,117 |
| Operating income | 3,578 | 3,991 | 4,047 |
| Pretax income | 5,231 | 4,780 | 4,199 |
| Net income | 4,505 | 4,413 | 3,954 |
| Diluted earnings per share | 41.48 | 38.34 | 34.77 |
Regeneron Pharmaceuticals balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 3,118 | 2,489 | 2,730 |
| Total assets | 40,559 | 37,759 | 33,080 |
| Total liabilities | 9,302 | 8,406 | 7,107 |
| Total equity | 31,257 | 29,354 | 25,973 |
| Long-term debt | 1,986 | 1,984 | 1,983 |
Regeneron Pharmaceuticals cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 4,979 | 4,421 | 4,594 |
| Capital expenditure | -898 | -756 | -719 |
| Free cash flow (derived) | 4,081 | 3,665 | 3,875 |
| Dividends paid | -370 | 0 | 0 |
| Share repurchases | -3,439 | -2,603 | -2,235 |
Quarterly highlights
| USD millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue (derived) | 5,116 | 4,291 | 3,605 | 3,884 |
| Operating income (derived) | 2,048 | 1,294 | 643 | 880 |
| Net income (derived) | 1,949 | 1,297 | 727 | 845 |
| Diluted earnings per share | 18.45 | 12.23 | 6.75 | n/a |
| Operating cash flow (derived) | 1,783 | 813 | 1,079 | 1,171 |
| Total assets | 44,405 | 41,731 | 40,869 | 40,559 |
Regeneron Pharmaceuticals major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| Vanguard Capital Management | 7.4% | 7,660,810 | 30 April 2026 |
Regeneron Pharmaceuticals 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 30 October 2026 | 10-Q | Quarterly report | Quarterly report |
| 30 October 2026 | 8-K | Current report | Current report |
| 6 October 2026 | 8-K | Current report | FORM 8-K |
| 30 September 2026 | 8-K | Current report | FORM 8-K |
| 30 July 2026 | 10-Q | Quarterly report | Quarterly report |
| 30 July 2026 | 8-K | Current report | Current report |
| 6 July 2026 | 8-K | Current report | FORM 8-K |
| 17 June 2026 | 8-K | Current report | FORM 8-K |
Common questions
What was Regeneron Pharmaceuticals' revenue in fiscal 2025?
Regeneron Pharmaceuticals reported $14.3 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 1.0% from fiscal 2024.
What was Regeneron Pharmaceuticals' net income in fiscal 2025?
Regeneron Pharmaceuticals reported net income of $4.5 billion for fiscal 2025, the year ended 31 December 2025, up 2.1% from fiscal 2024. Diluted earnings per share were $41.48.
What was Regeneron Pharmaceuticals' free cash flow in fiscal 2025?
Regeneron Pharmaceuticals had $4.1 billion in free cash flow in fiscal 2025. Operating cash flow was $5.0 billion and capital expenditure was $898 million.
What were Regeneron Pharmaceuticals' total assets at the end of fiscal 2025?
Regeneron Pharmaceuticals reported total assets of $40.6 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much Regeneron Pharmaceuticals history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.